Genenews Limited (GNWSF) 1.1590 $GNWSF
PDL BioPharma IncCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 8:03PM CST
Mr. Rory Riggs of 110 East 59th Street, 33rd Floor, Suite 3302, New York, NY, 10022, USA, chairman of the board of directors of GeneNews Limited (TSX: GEN) ("GeneNews"
announces that on December 14, 2012, Mr. Riggs completed a subscription for 4,139,400 common shares ("Common Shares" of GeneNews, at a price per Common Share of $0.09 through a previously announced private placement (the "Private Placement" by GeneNews.
GeneNews Implements Share Consolidation
CNW Group - Fri Dec 21, 3:45PM CST
GeneNews Limited (TSX: GEN) ("GeneNews" , a molecular diagnostics company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that its common shares (Symbol: GEN) (the "Shares" will be posted for trading at the opening of business on December 24, 2012, on a one-for-six consolidated basis (the "Consolidation" , resulting in 33,744,883 issued and outstanding Shares, under the new CUSIP number 36870T 20 6. The Consolidation was previously announced on December 7, 2012 and was approved by the shareholders of GeneNews on April 26, 2012.
Molecular Diagnostics - Global Strategic Business Report
M2 - Fri Dec 21, 8:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zps7t/molecular) has announced the addition of the "Molecular Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following Product Segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 103 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Life Technologies Corporation, Celera, Biom?rieux, CytoCore Inc., ELITech Group, GE Healthcare, Genzyme Corporation, Hologic, Inc., Laboratory Corporation of America? Holdings, MiraiBio, Inc., Novartis Diagnostics, QIAGEN N. V, Quest Diagnostics, In
PDL BioPharma IncCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 8:03PM CST
Mr. Rory Riggs of 110 East 59th Street, 33rd Floor, Suite 3302, New York, NY, 10022, USA, chairman of the board of directors of GeneNews Limited (TSX: GEN) ("GeneNews"
announces that on December 14, 2012, Mr. Riggs completed a subscription for 4,139,400 common shares ("Common Shares" of GeneNews, at a price per Common Share of $0.09 through a previously announced private placement (the "Private Placement" by GeneNews. GeneNews Implements Share Consolidation
CNW Group - Fri Dec 21, 3:45PM CST
GeneNews Limited (TSX: GEN) ("GeneNews"
, a molecular diagnostics company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that its common shares (Symbol: GEN) (the "Shares" will be posted for trading at the opening of business on December 24, 2012, on a one-for-six consolidated basis (the "Consolidation" , resulting in 33,744,883 issued and outstanding Shares, under the new CUSIP number 36870T 20 6. The Consolidation was previously announced on December 7, 2012 and was approved by the shareholders of GeneNews on April 26, 2012. Molecular Diagnostics - Global Strategic Business Report
M2 - Fri Dec 21, 8:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zps7t/molecular) has announced the addition of the "Molecular Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following Product Segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 103 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Life Technologies Corporation, Celera, Biom?rieux, CytoCore Inc., ELITech Group, GE Healthcare, Genzyme Corporation, Hologic, Inc., Laboratory Corporation of America? Holdings, MiraiBio, Inc., Novartis Diagnostics, QIAGEN N. V, Quest Diagnostics, In
